How Healthcare Marketers Can Still Drive Brand Growth With Falling Budgets
With healthcare budgets decreasing, market access and marketing teams at pharma companies are tasked with finding innovative ways to attract more patients and improve gross-to-nets, while keeping costs down.
How Pharma Manufacturers Are Changing Copay Programs To Combat Accumulators and Maximizers
Since the rise of accumulator and maximizer programs, many stakeholders within the pharmacy industry have been looking to tip the scales back towards traditional copay assistance models.
How Customized Copay Analytics Help Brands Build Market Share
Data needs vary from brand to brand. It’s critical for pharma brands to employ customized copay analytics strategies for their patient access programs.
3 Patient Access Strategies Setting Innovative Brands Apart
The gross-to-net bubble is inflating. What patient access strategies are leading brands using to combat this trend?
7 Indicators that Your Drug is a Strong Candidate for Accumulator and Maximizer Programs
How should pharma companies plan for if their drugs will be included in accumulator or maximizer programs? Use our interactive checklist.
The Accumulator Adjustment Ruling of 2023 – What’s Next for Brands
On May 17, 2022, the U.S. District Court for DC ruled against the “accumulator adjustment rule.” What impact will this have on pharma?
The Truveris Pharmacy Benefits Glossary of Terms
Truveris’ Pharmacy Benefits Glossary of Terms provides important definitions and context to help navigate the pharmacy benefits landscape.
3 Patient Access Strategies for New Biosimilar Brands
As biosimilars gain more popularity in the market, pharma manufacturers must think differently about launch strategies to gain market share.
What are Biosimilars and Why Do They Matter?
If you work in the pharmacy ecosystem, you’ve probably heard buzz around “biosimilars.” What should you know about this innovative type of medication?
6 Takeaways from the Asembia 2022 Specialty Pharmacy Summit
6,000 pharmacy professionals attended Asembia this year. What were the key takeaways from the conference?
What Self-Funded Plans Should Know About Copay Assistance Programs
Plan sponsors are looking for new ways to contain specialty costs. How should they evaluate new copay assistance strategies?
3 Ways to Avoid Drug Launch Mistakes
With so much importance placed on the launch of a new drug, how should pharma brands ensure a successful launch?
How are COVID-19 Variants Impacting Pharmaceutical Brands?
With Delta and Omicron, the COVID-19 pandemic carries on. How are these variants impacting pharma brands?
3 Strategies for Pharma Brands to Navigate the January Claims Drop
Many brands experience a drop in claims during January. What strategies successfully drive adherence during the beginning of the year?
Asembia 2021: Four Key Takeaways
Four core themes from Asembia 2021 that will drive dialogue in the specialty pharmacy ecosystem in 2022 – and beyond.
The 340B Program: How Manufacturers, Plan Sponsors, and Brokers Should React
340B is increasingly a part of the pharmacy conversation. How should stakeholders react to the program?
The Impact of COVID-19 on Brand Prescribing and Claims
Read Truveris’ data report on the impact of COVID-19 on pharma, specifically prescribing and claims numbers for branded drugs.
Gene Therapy and Cell Therapy: Key Payer Considerations
Many gene therapy products are soon to be released to the market. What do payers need to know about these highly-expensive specialty drugs?
5 Misconceptions about Loss of Exclusivity that Impact Patient Retention
Loss of exclusivity can feel like a dramatic shift, forever changing a drug’s profitability. However, this doesn’t have to be your brand’s fate.
Industry Update: The Impact of State Legislation on Copay Accumulator Programs
Several states have passed legislation that prohibits the use of copay accumulator adjustment programs. How does this affect your organization?
Generic Drug Differences and MAC Pricing: What Plan Sponsors Need to Know
Generic versions of brand name medications are not all the same. Understanding their differences and their implications on MAC pricing is critical for choosing the most cost-effective PBM.
Webinar - Payer Strategies for Anticipating and Managing Gene Therapy
Watch Truveris’ on-demand webinar outlining how Payers can best anticipate and manage new gene therapies.
What's the Difference between a Specialty Drug and a Non-Specialty Drug?
Looking forward to the future of pharmacy, it’s critical to understand how a specialty drug is defined, how it differs from traditional, non-specialty drugs, and how specialty is impacting employers’ benefit plan designs.
Three Ways to Help Patients Navigate the Medicare Coverage Gap
Many Medicare patients end up not filling their high-cost prescriptions due to the Medicare coverage gap. What can manufacturers do to help Medicare patients stay adherent?
3 Ways to Build Better Copay Assistance Programs
Adopting these three approaches can help manufacturers to build a more effective affordability program.
What is a Pharmacy Benefits Manager (PBM) and How Does a PBM Impact the Pharmacy Benefits Ecosystem?
Pharmacy Benefits Managers, also referred to as PBMs, are the intermediaries between every stakeholder in the pharmacy ecosystem.
Is Your Patient Abandonment Rate Really What You Think it is?
Your entire access strategy hinges on your patient abandonment rate. Is your patient abandonment rate calculated correctly?
Is Your Copay Program Costing You More Than It’s Earning? Keep These Top 5 Metrics In Mind
While the goals of every copay program vary, the top 5 essential ROI metrics to track its success stay the same.